PDF(Pubmed)
Abstract：
UNASSIGNED: Effective discrimination of lung adenocarcinoma (LUAD) in situ (AIS) from benign pulmonary nodules (BPN) is critical for the early diagnosis of AIS. Our pilot study in a small cohort of 90 serum samples has shown that serum interleukin 6 (IL-6) detection can distinguish AIS from BPN and health controls (HC). In this study, we intend to comprehensively define the diagnostic value of individual and combined detection of serum IL-6 related to the traditional tumor markers carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) for AIS.
UNASSIGNED: The diagnostic performance of serum IL-6 along with CEA and CYFRA21-1 were evaluated in a large cohort of 300 serum samples by a chemiluminescence immunoassay and an electrochemiluminescence immunoassay. A training set comprised of 65 AIS, 65 BPN, and 65 HC samples was used to develop the predictive model for AIS. Data obtained from an independent validation set was applied to evaluate and validate the predictive model.
UNASSIGNED: In the training set, the levels of serum IL-6 and CEA in the AIS group were significantly higher than those in the BPN/HC group (P < 0.05). There was no significant difference in serum CYFRA21-1 levels between the AIS group and the BPN/HC group (P> 0.05). Serum IL-6 and CEA levels for AIS patients showed an area under the curve (AUC) of 0.622 with 23.1% sensitivity at 90.7% specificity, and an AUC of 0.672 with 24.6% sensitivity at 97.6% specificity, respectively. The combination of serum IL-6 and CEA presented an AUC of 0.739, with 60.0% sensitivity at 95.4% specificity. The combination of serum IL-6 and CEA showed an AUC of 0.767 for AIS patients, with 57.1% sensitivity at 91.4% specificity in the validation set.
UNASSIGNED: IL-6 shows potential as a prospective serum biomarker for the diagnosis of AIS, and the combination of serum IL-6 with CEA may contribute to increased accuracy in AIS diagnosis. However, it is worth noting that further research is still necessary to validate and optimize the diagnostic efficacy of these biomarkers and to address potential sensitivity limitations.
UNASSIGNED: The diagnostic performance of serum IL-6 along with CEA and CYFRA21-1 were evaluated in a large cohort of 300 serum samples by a chemiluminescence immunoassay and an electrochemiluminescence immunoassay. A training set comprised of 65 AIS, 65 BPN, and 65 HC samples was used to develop the predictive model for AIS. Data obtained from an independent validation set was applied to evaluate and validate the predictive model.
UNASSIGNED: In the training set, the levels of serum IL-6 and CEA in the AIS group were significantly higher than those in the BPN/HC group (P < 0.05). There was no significant difference in serum CYFRA21-1 levels between the AIS group and the BPN/HC group (P> 0.05). Serum IL-6 and CEA levels for AIS patients showed an area under the curve (AUC) of 0.622 with 23.1% sensitivity at 90.7% specificity, and an AUC of 0.672 with 24.6% sensitivity at 97.6% specificity, respectively. The combination of serum IL-6 and CEA presented an AUC of 0.739, with 60.0% sensitivity at 95.4% specificity. The combination of serum IL-6 and CEA showed an AUC of 0.767 for AIS patients, with 57.1% sensitivity at 91.4% specificity in the validation set.
UNASSIGNED: IL-6 shows potential as a prospective serum biomarker for the diagnosis of AIS, and the combination of serum IL-6 with CEA may contribute to increased accuracy in AIS diagnosis. However, it is worth noting that further research is still necessary to validate and optimize the diagnostic efficacy of these biomarkers and to address potential sensitivity limitations.
摘要：
■有效区分肺腺癌（LUAD）原位（AIS）和良性肺结节（BPN）对于AIS的早期诊断至关重要。我们在90份血清样本的小队列中进行的初步研究表明，血清白细胞介素6（IL-6）检测可以将AIS与BPN和健康对照（HC）区分开。在这项研究中,我们打算全面定义单独和联合检测与传统肿瘤标志物癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA21-1）相关的血清IL-6对AIS的诊断价值。
■通过化学发光免疫测定和电化学发光免疫测定在300份血清样品的大队列中评估了血清IL-6以及CEA和CYFRA21-1的诊断性能。由65个AIS组成的训练集，65BPN,65个HC样本用于建立AIS的预测模型。应用从独立验证集获得的数据来评估和验证预测模型。
■在训练集中，AIS组血清IL-6、CEA水平明显高于BPN/HC组(P<0.05)。AIS组与BPN/HC组血清CYFRA21-1水平差异无统计学意义(P>0.05)。AIS患者的血清IL-6和CEA水平显示曲线下面积（AUC）为0.622，灵敏度为23.1％，特异性为90.7％，AUC为0.672，灵敏度为24.6%，特异性为97.6%，分别。血清IL-6和CEA的组合呈现0.739的AUC,60.0%的灵敏度和95.4%的特异性。血清IL-6和CEA的联合显示AIS患者的AUC为0.767，在验证组中，57.1%的敏感性和91.4%的特异性。
■IL-6显示出作为AIS诊断的前瞻性血清生物标志物的潜力，血清IL-6与CEA的联合可能有助于提高AIS诊断的准确性。然而,值得注意的是,仍需要进一步的研究来验证和优化这些生物标志物的诊断效能,并解决潜在的敏感性限制.
■通过化学发光免疫测定和电化学发光免疫测定在300份血清样品的大队列中评估了血清IL-6以及CEA和CYFRA21-1的诊断性能。由65个AIS组成的训练集，65BPN,65个HC样本用于建立AIS的预测模型。应用从独立验证集获得的数据来评估和验证预测模型。
■在训练集中，AIS组血清IL-6、CEA水平明显高于BPN/HC组(P<0.05)。AIS组与BPN/HC组血清CYFRA21-1水平差异无统计学意义(P>0.05)。AIS患者的血清IL-6和CEA水平显示曲线下面积（AUC）为0.622，灵敏度为23.1％，特异性为90.7％，AUC为0.672，灵敏度为24.6%，特异性为97.6%，分别。血清IL-6和CEA的组合呈现0.739的AUC,60.0%的灵敏度和95.4%的特异性。血清IL-6和CEA的联合显示AIS患者的AUC为0.767，在验证组中，57.1%的敏感性和91.4%的特异性。
■IL-6显示出作为AIS诊断的前瞻性血清生物标志物的潜力，血清IL-6与CEA的联合可能有助于提高AIS诊断的准确性。然而,值得注意的是,仍需要进一步的研究来验证和优化这些生物标志物的诊断效能,并解决潜在的敏感性限制.
